Celgene (CELG) Revlimid Estimates, PT Lifted at Nomura
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Celgene (CELG) Added to BofA/Merrill Lynch US 1 List
October 28, 2014 7:51 AM EDTBofA/Merrill Lynch added Celgene (NASDAQ: CELG) to its US 1 List while maintaining a Buy rating and price target of $112.00.
Analyst Ying Huang notes CELG is one of the highest growth companies among the large-cap biotechs and they expect compounded annual... More
Celgene (CELG) Price Target Raised to $134 at Deutsche Bank
October 24, 2014 9:07 AM EDTDeutsche Bank maintained a Buy rating on Celgene (NASDAQ: CELG) and raised its price target to $134.00 (from $115.00). Analyst Robyn Karnauskas said Celgene was emerging as top pick for 2015.
"The focus of the 3Q call was the strong Otezla launch, and the pipeline,... More
Celgene (CELG) Tops Q3 EPS by 2c
October 23, 2014 7:39 AM EDTCelgene (NASDAQ: CELG) reported Q3 EPS of $0.97, $0.02 better than the analyst estimate of $0.95. Revenue for the quarter came in at $1.96 billion versus the consensus estimate of $1.96 billion.
Net Product Sales Performance
REVLIMID® sales for the third quarter increased 19 percent to $1,300 million and were driven by volume in both the U.S. and International markets as a result of increased duration of therapy and continued market share leadership in multiple myeloma. U.S. sales of... More